CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 98 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04634253
NCT04634253Phase 2Completed
CompareCT.gov

A Phase 2 Study to Evaluate the Efficacy and Safety of LY3462817 in Participants With Moderately to Severely Active Rheumatoid Arthritis

Eli Lilly and Company·interventional·Posted Nov 18, 2020·Updated Jul 12, 2023

In Brief

A Phase 2 clinical trial evaluating Placebo and LY3462817 for Rheumatoid Arthritis. Completed, enrolled 98 participants across 26 sites in 7 countries.

Detailed Summary

The reason for this study is to see if the study drug LY3462817 is safe and effective in participants with moderately to severely active rheumatoid arthritis (RA).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesCzechia, Hungary, Mexico, Poland, Puerto Rico, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedNov 18, 2020
Enrollment StartJan 4, 2021
Primary CompletionJan 10, 2022
Study CompletionJun 29, 2022
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 5.6 years ago

Interventions

Placebodrug

Given IV

LY3462817drug

Given IV